Phase II trial

Non-small cell lung cancer
#Checkpoint inhibitor therapies #iOnctura #Lung cancer #Non-small cell lung cancer (NSCLC) #Phase II trial

Cancer ‘master switch’ study expands to lung cancer

iOnctura has expanded its clinical trial programme for roginolisib to include non-small cell lung cancer (NSCLC). Via clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK, roginolisib will be evaluated in a Phase II study in combination with dostarlimab in patients with NSCLC… Read More

#Cancer Research #News

MRI of the brain
#AviadoBio #Dementia #Gene therapy #Neurodegenerative disorders #Phase II trial

Gene therapy trial starts in early-onset dementia

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. ASPIRE-FTD is evaluating investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). The study is also recruiting in Europe with… Read More

#News

Immune thrombocytopenia test
#Events #ITP #Monoclonal antibodies #Phase II trial #Takeda

Favourable results for mAb in bleeding disorder shared at ISTH

Takeda has shared positive results from its Phase IIb study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterised by the accelerated destruction of platelets in blood, resulting… Read More

#News

Cell and gene therapies
#AskBio #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy for Parkinson’s disease progresses to Phase II

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and… Read More

#News

#EG 427 #Gene therapy #Neurology #Phase II trial

First gene therapy for bladder condition enters clinical study

Biotechnology company EG 427 has revealed plans to start a Phase Ib/IIa clinical study in neurogenic detrusor overactivity (NDO), following Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA). NDO is a severe bladder condition affecting patients living with spinal cord injury,… Read More

#News

Neurons
#Alzheimer's #Neurodegenerative disorders #Phase II trial #Regenerative Medicine #Spinogenix

Synapse-regenerating drug could reverse decline in Alzheimer’s

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia. The study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of SPG302 in adult AD participants. Read More

#News

Lungs
#Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Insilico Medicine #Phase II trial

Idiopathic pulmonary fibrosis study completes enrolment

Insilico Medicine has completed patient enrolment in a Phase IIa study in China, which is investigating the safety, tolerability, and preliminary efficacy of AI-designed TNIK inhibitor INS018_055 for idiopathic pulmonary fibrosis (IPF). The randomised, double-blind, placebo-controlled study is being conducted across 29 clinical centres in China… Read More

#News

CAR-T for large B-cell lymphoma
#Allogene Therapeutics #allogeneic cell therapies #Cell therapy #Lymphoma #Oncology #Phase II trial

Phase II trial investigates allogeneic CAR-T for large B-cell lymphoma

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse. The ALPHA3 trial will… Read More

#Cancer Research #News

Business financing
#AltruBio #Antibody #Financing #Phase II trial #Ulcerative colitis (UC)

$225m to advance novel immune checkpoint enhancer programme

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. The funds will be used to support ongoing and planned Phase II clinical trials in ulcerative… Read More

#Business & Investment #News

Parkinson's disease
#AskBio #Cell and gene therapy #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy proved to be safe in patients with Parkinson’s disease

Askbio’s AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no serious adverse events in a Phase Ib clinical trial. The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado,… Read More

#News #Trending News

Lungs
#Chronic obstructive pulmonary disease (COPD) #EpiEndo #Non-antibiotic macrolides #Phase II trial

Positive results announced for COPD therapy

Biopharmaceutical company EpiEndo has completed a Phase IIA clinical trial for its therapy addressing chronic obstructive pulmonary disease (COPD). EpiEndo is developing orally available, non-antibiotic macrolides, or Barriolides, that reduce inflammation while also limiting antimicrobial resistance (AMR). The company’s lead asset is EP395 and it focuses… Read More

#News

#Alta Neuroscience #Depression #Major depressive disorder #Neuroscience #Phase II trial

Major depressive disorder drug progresses to Phase II trials

Alto Neuroscience has initiated a Phase II study to determine the pharmacodynamic effects of ALTO-203 in major depressive disorder (MDD) patients, as well as assess its safety, tolerability, and pharmacokinetics. To date, ALTO-203 has demonstrated positive emotional and cognitive effects in healthy participants after a single… Read More

#News

Gut microbiome
#EnteroBiotix #Gut microbiome #Irritable Bowel Syndrome #Microbiome #Phase II trial

Microbiome drug to be tested in IBS clinical trial

EnteroBiotix, a Glasgow, UK based biotechnology company, has dosed the first patient in a clinical trial designed to evaluate EBX-102-02 for the treatment of irritable bowel syndrome (IBS). The Phase II study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol… Read More

#News

Alcohol use disorder
#Alcohol Use Disorder #Beckley Psytech #Phase II trial #Psychedelics

Could a novel psychedelic treat alcohol use disorder?

A novel psychedelic compound, combined with psychological support, will be explored as a potential new treatment for people living with alcohol use disorder (AUD) in a Phase IIa study. The trial uses Beckley Psytech’s lead candidate BPL-003, a short-duration and fast-acting synthetic formulation of psychedelic mebufotenin… Read More

#News

#Cardiovascular disease #FDA #Hypertension #Idorsia #Phase II trial

FDA approval represents ‘transformational progress’ in hypertension

The US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Tryvio (aprocitentan) is an endothelin receptor antagonist that inhibits the binding of endothelin… Read More

#News #Regulatory #Trending News